$1.38—Stale · unknown old
NASDAQ • Last print unknown ago
$1.38—Stale · unknown old
INM News
About
inmed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. inmed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company.
Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Eric Adams
Country
Canada
Website
Leadership (8)
Eric A. Adams Chem.President, Chief Executive Officer & Director
N. Netta JagpalChief Financial Officer & Corporate Secretary
Michael WoudenbergChief Operating Officer
Eric Chih-Hsien HsuSenior Vice President of Preclinical Research & Development
Sazzad HossainCo-Founder
Shane A. JohnsonSenior Vice President & GM of BayMedica
Colin ClancyVP of Investor Relations & Corporate Communications
Jerry GriffinVice President of Sales & Marketing
Explore More
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Strategy Focus List
Continuous multi-factor scoring & catalyst forensics
Market Movers
Today's biggest gainers and losers